Abstract：Objective：To observe the clinical efficacy of Maxing Shigan Decoction plus Sangbaipi Decoction as an adjunctive treatment to western medicine for bronchopneumonia with accumulation of phlegm-heat in lung syndrome. Methods：A total of 100 patients with bronchopneumonia with accumulation of phlegm-heat in lung syndrome，treated in the Department of Traditional Chinese Medicine，the Seventh Medical Center of the Chinese PLA General Hospital from October 2022 to October 2024， were selected and randomly divided into the control group and the observation group using the random number table method， with 50 cases in each group. One case dropped out from each group during the study. The control group received western medicine treatment，while the observation group received Maxing Shigan Decoction plus Sangbaipi Decoction in addition to the control group's treatment. Both groups were treated for two weeks. Clinical efficacy， incidence of adverse reactions were compared between the two groups. Traditional Chinese medicine syndrome scores， inflammatory markers [C-reactive protein （CRP）， interleukin-6 （IL-6）， interferon- γ （IFN-γ）]， oxidative stress indicators [malondialdehyde （MDA）， glutathione peroxidase （GSH-Px）]， and lung function indicators [forced expiratory volume in one second （FEV1）， forced vital capacity （FVC）， peak expiratory flow （PEF）] before and after treatment were compared between the two groups. Results：After two weeks of treatment， the total effective rate in the observation group was higher than that in the control group （P＜0.05）. Traditional Chinese medicine syndrome scores decreased in both groups compared with those before treatment （P＜0.05），and the score in the observation group was lower than that in the control group （P＜0.05）. Serum levels of CRP，IL-6，IFN-γ，and MDA decreased in both groups compared with those before treatment （P＜0.05）， and the levels in the observation group were lower than those in the control group （P＜0.05）. Serum GSH-Px levels increased in both groups compared with those before treatment （P＜0.05）， and the level in the observation group was higher than that in the control group（ P＜0.05）. Values of FEV1，FVC，and PEF increased in both groups compared with those before treatment（ P＜ 0.05）， and the values of these three lung function indicators in the observation group were higher than those in the control group （P＜0.05）. There was no statistically significant difference in the incidence of adverse reactions between the two groups （P＞0.05）. Conclusion：Maxing Shigan Decoction plus Sangbaipi Decoction as an adjunctive treatment to western medicine for bronchopneumonia with accumulation of phlegm-heat in lung syndrome can improve efficacy， alleviate clinical symptoms，reduce inflammatory response and oxidative stress，and enhance lung function.